In brief: Benitec, XRT, Phylogica, Norwood Abbey
Wednesday, 06 April, 2005
RNAi specialist Benitec (ASX:BLT) has lodged a prospectus with ASIC to raise up to AUD$9.7 million in a rights issue, underwritten by Bell Potter. Capital raised will go towards clinical development and expansion of Benitec's California operations, it said.
Unlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal in which an unnamed analytical company will incorporate XRT's phase contrast technology in 3D metrology and analysis instruments.
Drug discovery firm Phylogica (ASX:PYC) has named former Peptech and CSL executive Dr Greg Pullen as its chief operating officer. Most recently, Pullen was in charge of licensing at Auckland University's commercialisation entity.
Norwood Abbey (ASX:NAL) has won TGA approval for a key component of its vision correction surgery tool Epi-Lasik.
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
